See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A man has been arrested after the death of Tasia Fortune, a 29-year-old ...
Three jurors from the Lindsay Clancy murder trial, which ended in a mistrial, have come forward to discuss the deliberations. The jury’s foreperson, who wrote the note indicating concerns about a ...
While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity in ...
Lepodisiran is currently in the Phase 3 ACCLAIM-Lp (a) trial, with initial data expected in 2029, while olpasiran’s OCEAN (a) study is slated for a topline readout in 2028. “We do see meaningful risk ...
Novartis will analyze the full dataset and talk to health authorities to determine the next steps. (Sedat Suna/Getty Images) The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary ...
After Novo Nordisk and AstraZeneca, Novartis is the third big pharma to suffer a major cardiovascular outcomes trial failure in the past two months. The Swiss pharma reported Friday ...
Analysts at William Blair were “disappointed” by the data but said they had always viewed Ultragenyx's trial as “high risk, high reward.” (iStock / Getty Images Plus) Ultragenyx had been flying high ...
A pub group is seeking to repossess three of its tenanted venues. Greene King is following a legal process over The Bunbury Arms, in Great Barton, The Linden Tree, in Bury St Edmunds, and Three Kings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results